NYSE · JNJ
Johnson & Johnson
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for JNJ has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $2.91 | $2.95 | $2.86 | 7 |
| Mar 2027 | $2.72 | $2.88 | $2.57 | 3 |
| Jun 2027 | $2.95 | $3.13 | $2.80 | 3 |
| Sep 2027 | $2.79 | $2.82 | $2.74 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · RTTNews- Zacks · Oct 30, 9:23 AM EDTJNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4?J&J's MedTech growth slows in Q3 amid international market challenges and Abiomed weakness.
- The Motley Fool · Oct 30, 4:20 AM EDTWarren Buffett Says Most Investors Should Buy the S&P 500. Here's How Much You Can Actually Earn With This ETF.Warren Buffett famously said to “never bet against America” and encouraged investors to buy a low-cost S&P 500 index fund.
- Zacks · Oct 29, 8:30 AM EDTJohnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?According to the average brokerage recommendation (ABR), one should invest in Johnson & Johnson (JNJ). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
- The Motley Fool · Oct 29, 7:05 AM EDT3 Unstoppable S&P 500 Stocks to Buy Before October EndsCoca-Cola is excelling during a difficult time for consumer staples companies.
- Zacks · Oct 28, 10:45 AM EDTGSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines SalesGSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
- Zacks · Oct 28, 3:29 AM EDTThe Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVieEli Lilly, Novartis, Johnson & Johnson and AbbVie advance arthritis treatment portfolios through strong drug sales, clinical progress and regulatory expansions.
- Zacks · Oct 27, 11:16 AM EDT4 Arthritis Drug Stocks Investors Should Monitor for Growth PotentialLLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.
- Zacks · Oct 27, 10:32 AM EDTBuy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 EarningsAbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise near-term concerns.
- Zacks · Oct 27, 7:56 AM EDTIs Merck Stock a Buy, Sell or Hold Ahead of Q3 Earnings?MRK heads into Q3 earnings with strong Keytruda sales and new drug growth, but declining estimates, Gardasil weakness and looming patent risks cloud its outlook.
- RTTNews · Oct 26, 6:57 AM EDTJ&J's RYBREVANT FASPRO Combo Delivers 77% Response Rate In Head And Neck Cancer(RTTNews) – Johnson & Johnson (JNJ) reported Phase 1b/2 results showing that RYBREVANT FASPRO combined with pembrolizumab and carboplatin demonstrated substantial anti-tumor activity in patients receiving first-line treatment for recurrent or metastatic head and neck squamous cel
- RTTNews · Oct 26, 1:19 AM EDTJohnson & Johnson Posts Positive Phase 1b/2 Data Of Amivantamab Combo In Head And Neck Cancer(RTTNews) – Johnson & Johnson (JNJ) announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study demonstrating deep and durable responses, with 65% remaining ongoing at the clinical cut-off with first-line subcutaneous amivantamab and hyaluronidase-lpuj plus a PD-1 inhib
- RTTNews · Oct 25, 10:12 AM EDTJ&J's RYBREVANT FASPRO Regimen Delivers 77% Response Rate In First-Line HNSCC Study(RTTNews) – Johnson & Johnson (JNJ) announced new data from Cohort 5 of the Phase 1b/2 OrigAMI-4 study showing deep and durable responses with first-line subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO) combined with a PD-1 inhibitor and fixed-duration carboplat
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Johnson & Johnson from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.